Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1489MR)

This product GTTS-WQ1489MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1489MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11108MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ737MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ235MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ14915MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8257MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ1284MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ511MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ5843MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW